Treats T. vaginalis infection in females and males. ANDA 79067, held by Alembic Pharmaceuticals. Metronidazole.
As of Nov 21, 2026, ANDA 79067 (Metronidazole), held by Alembic Pharmaceuticals, was first approved by FDA on Mar 13, 2009, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Symptomatic Trichomoniasis. Metronidazole tablets USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets USP are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 13, 2009 | Original application | Approved | None posted |
| Metronidazole250MG · tablet;oral | Metronidazole | Rx |
| Metronidazole500MG · tablet;oral | Metronidazole | Rx |
| Jul 8, 2024 | Supplement 23Labeling · Standard review | Approved | None posted |
| Jun 28, 2024 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jun 28, 2024 | Supplement 18Labeling · Standard review | Approved | None posted |
| Aug 18, 2021 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jul 24, 2019 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jul 24, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 11, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 13, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters